Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability - PubMed (original) (raw)
. 2014 Nov;35(11):3071-80.
doi: 10.1016/j.ridd.2014.07.060. Epub 2014 Aug 15.
Affiliations
- PMID: 25129201
- DOI: 10.1016/j.ridd.2014.07.060
Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability
Syed Imran Haider et al. Res Dev Disabil. 2014 Nov.
Abstract
Although polypharmacy is a medication safety concern leading to increased risk of non-adherence, adverse drug reaction and drug-drug interactions, polypharmacy and associated risk factors has rarely been investigated involving people with ID at a population level. The purpose of this paper is to analyze the prevalence of polypharmacy and to evaluate the role of different factors associated with polypharmacy in a state-wide representative population of adults with ID. In a population-based survey in Victoria, Australia, 897 people with ID 18 years of age or older were selected by simple random sampling. The data were collected from proxy respondents on behalf of people with ID. Polypharmacy was defined as the concomitant use of five or more medications. The data were weighted to reflect the age/sex/geographic distribution of the population. Results revealed that more than 76% of adults with ID had used prescribed medicine and about 21% were exposed to polypharmacy in the last two weeks. In both univariate and multivariate analyses, polypharmacy was significantly associated with older age, unemployment and inability to get help from family and friends if needed. After controlling for age, sex and severity of intellectual disability, polypharmacy was associated with having a blood pressure, blood cholesterol and blood glucose level check. Polypharmacy was also associated with a greater number of visits to general practitioners, fair or poor reported health status and inability to walk unaided. Subjects with epilepsy, diabetes, stroke, osteoporosis and cancer had a higher probability of polypharmacy. None of the disease inducing behaviors was associated with polypharmacy. This study highlights the need that medication should be regularly reviewed overall in ID population and particularly when polypharmacy exists.
Keywords: Developmental disability; Intellectual disability; Medicine use; Pharmacoepidemiology; Polypharmacy.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
- Health and wellbeing of Victorian adults with intellectual disability compared to the general Victorian population.
Haider SI, Ansari Z, Vaughan L, Matters H, Emerson E. Haider SI, et al. Res Dev Disabil. 2013 Nov;34(11):4034-42. doi: 10.1016/j.ridd.2013.08.017. Epub 2013 Sep 13. Res Dev Disabil. 2013. PMID: 24036484 - Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland.
O'Dwyer M, Peklar J, Mulryan N, McCallion P, McCarron M, Henman MC. O'Dwyer M, et al. J Intellect Disabil Res. 2017 Oct;61(10):969-983. doi: 10.1111/jir.12391. Epub 2017 Jun 21. J Intellect Disabil Res. 2017. PMID: 28639298 - Chronic kidney disease in older people with intellectual disability: results of the HA-ID study.
de Winter CF, Echteld MA, Evenhuis HM. de Winter CF, et al. Res Dev Disabil. 2014 Mar;35(3):726-32. doi: 10.1016/j.ridd.2013.11.005. Epub 2013 Nov 25. Res Dev Disabil. 2014. PMID: 24287320 - Relationship between anti-seizure medication and behaviors that challenge in older persons with intellectual disability and epilepsy: a review.
Moon S, Watkins L, O'Dwyer M, Shankar R. Moon S, et al. Expert Rev Neurother. 2024 Nov;24(11):1097-1105. doi: 10.1080/14737175.2024.2393322. Epub 2024 Aug 19. Expert Rev Neurother. 2024. PMID: 39160772 Review. - Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability.
Eady N, Courtenay K, Strydom A. Eady N, et al. Drugs Aging. 2015 Feb;32(2):95-102. doi: 10.1007/s40266-014-0236-7. Drugs Aging. 2015. PMID: 25573538 Review.
Cited by
- Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines.
Sullivan WF, Diepstra H, Heng J, Ally S, Bradley E, Casson I, Hennen B, Kelly M, Korossy M, McNeil K, Abells D, Amaria K, Boyd K, Gemmill M, Grier E, Kennie-Kaulbach N, Ketchell M, Ladouceur J, Lepp A, Lunsky Y, McMillan S, Niel U, Sacks S, Shea S, Stringer K, Sue K, Witherbee S. Sullivan WF, et al. Can Fam Physician. 2018 Apr;64(4):254-279. Can Fam Physician. 2018. PMID: 29650602 Free PMC article. - Prevalence and Covariates of Polypharmacy in Elderly Patients on Discharge from a Tertiary Care Hospital in Oman.
Al-Hashar A, Al Sinawi H, Al Mahrizi A, Al-Hatrushi M. Al-Hashar A, et al. Oman Med J. 2016 Nov;31(6):421-425. doi: 10.5001/omj.2016.85. Oman Med J. 2016. PMID: 27974957 Free PMC article. - Prevalence of Polypharmacy and Inappropriate Medication in Adults With Intellectual Disabilities in a Hospital Setting in Switzerland.
Lonchampt S, Gerber F, Aubry JM, Desmeules J, Kosel M, Besson M. Lonchampt S, et al. Front Psychiatry. 2021 Jun 25;12:614825. doi: 10.3389/fpsyt.2021.614825. eCollection 2021. Front Psychiatry. 2021. PMID: 34248693 Free PMC article. - Deprescribing NSAIDs: The Potential Role of Community Pharmacists.
Amedi D, Gazerani P. Amedi D, et al. Pharmacy (Basel). 2024 Jul 24;12(4):116. doi: 10.3390/pharmacy12040116. Pharmacy (Basel). 2024. PMID: 39195845 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources